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The two-pore domain Kþ channel K2P5.1 has been implicated in the pathogenesis of autoimmune dis-
eases. We investigated the changes in K2P5.1 activity caused by a defect in normal pre-mRNA splicing in
concanavalin A-activated mouse splenic CD4þ T cells. The pre-mRNA splicing inhibitor, pladienolide B
(1 mM) markedly decreased full-length K2P5.1 transcription in activated CD4
þ T cells, resulting in the
disappearance of K2P5.1 activity and an imbalance in Th17 and Treg cytokines. These results suggest that
the defect in K2P5.1 splicing by the pre-mRNA splicing inhibitor regulates pro- and/or anti-inﬂammatory
cytokine production in K2P5.1-associated autoimmune diseases.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Pre-mRNA splicing inhibition is a novel therapeutic strategy in
cancer therapy (1,2), and many pre-mRNA splicing inhibitors have
recently been developed (3,4). The alternative splicing of ion
channels dysregulates their activity, kinetics, and membrane traf-
ﬁcking (5). The background, two-pore domain Kþ channel K2P5.1
plays an important role in cell volume regulation and Ca2þ
signaling (6), and dysregulated K2P5.1 is associated with the path-
ogenesis of autoimmune diseases such as rheumatoid arthritis and
inﬂammatory bowel disease (7,8). However, selective K2P5.1
blockers are not currently available. We recently identiﬁed func-
tionally defective splicing isoforms of K2P5.1, K2P5.1B from
lymphoid tissues (9), and the treatment with the pre-mRNA
splicing inhibitor, pladienolide B (PB) (Bioaustralis, Smithﬁeld,
Australia) suppressed K2P5.1 activity by upregulating the expres-
sion of K2P5.1B in the human leukemic cell line K562 (9). The
objective of the present study is to elucidatewhether K2P5.1 activity
is dysregulated by a defect in normal pre-mRNA splicing in acti-
vated cluster of differentiation 4-positive (CD4þ) T cells. Maleogy, Division of Pathological
-Nakauchi, Yamashina, Kyoto
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d/4.0/).C57BL/6J (6e7 weeks of age) mice were purchased from Shimizu
Laboratory Supplies (Kyoto, Japan). K2P5.1 homozygous knockout
(K2P5.1/) mice (B6; CB-Kcnk5Gt(pU-21)81Imeg) were generated
by crossing heterozygous (K2P5.1þ/) males with K2P5.1þ/ females
(8). All experiments were performed in accordance with the guid-
ing principles for the care and use of laboratory animals in Kyoto
Pharmaceutical University (KPU), and protocols were approved by
the committee on the Ethics of Animal Research of KPU (Permit
Number: 15-12-091). Mouse splenocytes were prepared inmedium
containing RPMI 1640 (Wako Pure Chemical Industries, Osaka,
Japan) supplemented with 10% heat-inactivated fetal calf serum in
the presence of the lectin, concanavalin A (Con A, 5 mg/mL) as
previously reported (10). Thirty hours after the cultivation of
splenocytes in Con A-supplemented medium, cell suspensions
were treated with vehicle control (dimethyl sulfoxide at a ﬁnal
concentration of 0.1%) and 0.1 or 1 mM PB. Eighteen hours after PB
treatment, CD4þ cells were isolated from splenocyte suspensions
using the Dynabeads® FlowComp™ Mouse CD4þ kit (Invitrogen,
Grand Island, NY, USA). A ﬂow cytometric analysis conﬁrmed that
more than 95% of the puriﬁed T cells were CD4þ. Cell viability was
monitored by a WST-1 assay (Dojindo, Kumamoto, Japan) (9).
Membrane potential was measured using the ﬂuorescent voltage-
sensitive dye DiBAC4(3) (Dojindo), as previously reported (see
‘Electric Supplementary Materials’) (8,9).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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treated CD4þ cells, and the resulting cDNA products were ampliﬁed
with gene-speciﬁc primers, designated using Primer Express™
software (Ver 1.5, Applied Biosystems, Foster City, CA, USA). The
PCR ampliﬁcation of full-length K2P5.1 was performed using KODFig. 1. Transcriptional expression levels of pro- and anti-inﬂammatorycytokines, a transcriptio
by Con A for 48 h, and the inhibition of alkaline pH (pH 8.5)-induced hyperpolarization respon
cloﬁlium. AeG: Quantitative real-time PCR assay for the expression of CD25 (A), IL-10 (B), IFN-g
alkaline pH (pHe 8.5)-induced hyperpolarization responses in activated CD4þ cells using the
ﬂuorescent intensity of DiBAC4(3) in vehicle (blue)- and cloﬁlium (10 mM, red)-pretreated group
colors from blue (low intensity/hyperpolarizing) to red (high intensity/depolarizing) in vehicle
changes in the relative ﬂuorescent intensity of DiBAC4(3) (Drelative FDiBAC) in activated CD4þ ce
activated CD4þ cells of K2P5.1/mice (n¼ 29). Results were expressed as means ± SEM. **P <FX Neo DNA polymerase (Toyobo, Tokyo, Japan). The ampliﬁcation
proﬁle was as follows: a 10-sec denaturation step at 98 C and a
1.5-min primer extension step at 68 C for 40 cycles. Gene-speciﬁc
primers were designated based on the cloned mouse K2P5.1
(mK2P5.1) [GenBank accession number: NM_021542 (codingnal factor, HIF-1a, a Treg cellmarker, CD25, andK2P5.1 in activatedmouse splenic CD4þ cells
ses in activated CD4þ cells by a pretreatment with the non-selective Kþ channel inhibitor,
(C), IL-17A (D), IL-2 (E), K2P5.1 (F), and HIF-1a (G) (n¼ 4 for each). HeK:Measurement of
voltage-sensitive ﬂuorescent dye DiBAC4(3). ‘H’ shows the time course of changes in the
s. Fluorescent intensity at 0 s (pHe 7.4) is expressed as 1.0. Images ‘I’ are shown in pseudo-
- and cloﬁlium (10 mM)-pretreated groups. Bar, 10 mm. Summarized data (J) are shown as
lls pretreated with vehicle (n¼ 29) and cloﬁlium (n¼ 35). ‘K’ shows summarized data in
0.01 vs. splenic CD4þ cells at day 0 (‘native’) (A, B, D, F, G) and vehicle-pretreated cells (J).
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obtained were ligated into pcDNA3.1(þ)/Neor (Invitrogen), and
DNA sequences were obtained using a custom DNA sequencing
service (Euroﬁns Genomics, Tokyo, Japan). Quantitative real-time
PCR was performed as described in ‘Electric Supplementary
Materials’. The signiﬁcance of differences was evaluated using the
Student's t-test after the F test.
We ﬁrst examined the effects of a Con A stimulation for 48 h on
K2P5.1 expression and activity and the transcriptional expression
levels of 1) cytokines [interleukin (IL)-2, IL-17A, IL-10, and interferon
(IFN)-g] with pro- and anti-inﬂammatory properties, 2) the tran-
scription factor, hypoxia inducible factor (HIF)-1a and 3) the regu-
latory T (Treg) cell marker, IL-2 receptor a-chains (CD25) in mouse
splenic CD4þ Tcells. Similar to the results obtained in thymic cells of
the duck, chicken, and turkey reported by Shanmugasundaramet al.Fig. 2. Molecular cloning of full-length K2P5.1 from mouse splenic CD4þ cells treated with v
induced hyperpolarization responses in activated CD4þ cells of wild-type and K2P5.1/mice
treated with vehicle and PB (1 mM) for full-length K2P5.1 by 1.0% agarose gel electrophoresis
alkaline pH (pHe 8.5)-induced hyperpolarization responses in activated CD4þ cells treated w
in the ﬂuorescent intensity of DiBAC4(3) in vehicle (blue)- and PB (1 mM, red)-treated grou
pseudo-colors in vehicle- and PB (1 mM)-treated groups. Bar, 10 mm. Summarized data are sh
were expressed as means ± SEM. Numbers used for the experiments were shown in paren(11), the expression levels of CD25 and IL-10 in CD4þ cells were
markedly increased by the ConA stimulation for 48 h (Fig.1A and B).
In mammalian, Lv et al. (2012) has indicated the Con A adminis-
tration increases CD4þCD25þ cell population relative to total CD4þ
cells, however, CD4þCD25þ cell population is approximately 15%
and the expression levels of IL-10 remains undetermined (12). This
is theﬁrst invitro study to showtheConA-induceddifferentiationof
CD4þCD25IL-10 cells into CD4þCD25þIL-10þ cells in mammalian
species. The percentages of the CD4þCD25þ cell population relative
to total CD4þ cells in native and Con A-stimulated CD4þ cells, as
analyzed by ﬂow cytometry, were 11.3 ± 0.4 (n¼ 6) and 53.3 ± 2.6%
(n ¼ 4), respectively (P < 0.01). The expression of the Th (helper T
cell) 1-cytokines, IFN-g and IL-2 remained unchanged (Fig. 1C and
E), whereas that of the Th17-cytokine, IL-17A was signiﬁcantly
decreased (Fig. 1D). Kirkegaads et al. (2016) (13) recently reportedehicle and PB (1 mM) for 18 h, and effects of the PB treatment on alkaline pH (pH 8.5)-
. A: A representative gel image of PCR products (for 40 cycles) from activated CD4þ cells
. PCR products were visualized with ethidium bromide staining. BeE: Measurement of
ith PB [1 (B, C, E) and 0.1 mM (D)] using DiBAC4(3). ‘B’ shows the time course of changes
ps. Fluorescent intensity at 0 s (pHe 7.4) is expressed as 1.0. Images ‘C’ are shown in
own as Drelative FDiBAC in vehicle- and PB [0.1 (D) and 1 mM (E)]-treated groups. Results
theses. **P < 0.01 vs. vehicle control.
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in CD3/CD28-activated human T cells. Shin et al. (2014) (14) also
showed the HIF-1a-mediated upregulation of K2P5.1 in mouse B
cells. Similarly, the expression levels of K2P5.1 andHIF-1a transcripts
were increased in activated CD4þ cells (Fig. 1F and G). Alkaline pH-Fig. 3. Effects of PB (1 mM, for 18 h) and CLF (10 mM, for 24 h) treatments on transcriptional
activated splenic CD4þ cells. AeF: Quantitative real-time PCR assay for the expression of CD
(n ¼ 4 for each). GeL: Quantitative real-time PCR assay for the expression of CD25 (G), IL-1
each). Results were expressed as means ± SEM. **P < 0.01 vs. vehicle control.induced hyperpolarization responses in Con A-stimulated CD4þ
cells were almost completely (over 90%) inhibited by 10 mM cloﬁ-
lium (CLF) (Sigma, St. Louis, MO, USA), a non-selective Kþ inhibitor
(Fig.1HeJ). In Con A-stimulated CD4þ cells prepared from K2P5.1/
mice, the alkaline pH stimulation rather depolarized the cellsexpression levels of pro- and anti-inﬂammatory cytokines, HIF-1a and CD25 in Con A-
25 (A), IL-10 (B), IFN-g (C), IL-17A (D), IL-2 (E), and HIF-1a (F) in PB-treated CD4þ cells
0 (H), IFN-g (I), IL-17A (J), IL-2 (K), and HIF-1a (L) in CLF-treated CD4þ cells (n ¼ 4 for
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alkaline pH-activated K2P Kþ channels.
We subsequently identiﬁed K2P5.1 isoforms in Con A-stimulated
CD4þ cells treated with vehicle or 1 mM PB for 18 h. As shown in
Fig. 2A, the predicted PCR product of full-length K2P5.1 with a
molecular weight of approximately 1.7 kbp was observed in the
vehicle-treated group but not in the PB-treated group. Ladder and
smear fragments with molecular weights of less than 1 kbp were
detected in the PB-treated group, whereas no spliced isoforms of
K2P5.1 were identiﬁed. A PCR fragment with a molecular weight of
approximately 1.5 kb was obtained by an additional 5 cycles of PCR
(total 45 cycles) in the PB-treated group (not shown) and a tran-
script variant X1 of K2P5.1 (GenBank accession number,
XM_006518590) lacking three transmembrane domains (S1eS3)
and the ﬁrst pore domain (P1) was identiﬁed. A dominant-negative
spliced isoform of K2P5.1, K2P5.1B, which we previously cloned from
the mouse spleen (9), was not identiﬁed in the present study.
Alternative splicing is an essential mechanism for increasing
functional diversity: however, many spliced isoforms have rarely
been expressed and have not produced functional proteins.
Therefore, the spliced isoforms produced by the PB treatment may
be unstable in native T cells.
PCR cloning experiments showed the disappearance of full-
length K2P5.1 expression by the PB treatment for 18 h. In order to
elucidate the inhibitory effects of PB on K2P5.1 activity, alkaline pH
(pH 8.5)-induced hyperpolarization responses were measured in
Con A-stimulated CD4þ cells. Alkaline pH-induced hyperpolar-
ization responses were signiﬁcantly inhibited by the treatment
with 1 mM PB (Fig. 2B, C, E), but not 0.1 mM PB (Fig. 2D). When
changes in the relative intensity of DiBAC4(3) were expressed as
‘relative DFDiBAC’, its peak amplitude was signiﬁcantly lower in
activated CD4þ cells of the 1 mM PB-treated group (Fig. 2E). As
shown in Fig. 3A, B, and D, the differentiation of Th17 into Treg was
almost fully recovered by the PB treatment, suggesting that PB
regulates the T cell differentiation. As shown in Fig. 3F, no signiﬁ-
cant change in HIF-1a expression was found in PB-treated CD4þ
cells, suggesting that the transcriptional activity of K2P5.1 is not
affected by the PB treatment. Indeed, no signiﬁcant differences of
the expression levels of K2P5.1 transcripts were found between the
groups before and after treatment with PB: 0.016 ± 0.003 and
0.018 ± 0.005, respectively (n¼ 4 for each, P > 0.05). The treatment
with 10 mM CLF for 48 h suppressed the upregulation of CD25 and
IL-10 (Fig. 3G and H) and downregulation of IL-17A (Fig. 3J) in Con
A-stimulated CD4þ cells. These results suggest that dysfunction of
K2P5.1 pre-mRNA splicing by PB treatment may be involved, at least
in part, in PB-induced recovery of differentiation into Treg cells.
Defects in normal splicing patterns are known to modify human
diseases. The main result of the present study is the down-
regulation of full-length K2P5.1 and the resulting functional defect
in K2P5.1 by the treatment with the pre-mRNA splicing inhibitor in
activated CD4þ cells. The pre-mRNA splicing inhibition prevented
Con A-induced T cell differentiation into Treg cells, and the K2P5.1
inhibition was at least in part involved in this process. We previ-
ously reported that the upregulation of K2P5.1 in inﬂammatory
CD4þ cells may be involved in the pathogenesis of inﬂammatory
bowel disease (IBD) (8). We examined the effects of the subcu-
taneous administration of PB (0.1 mg/kg/day) on IBD disease scores
(weight loss, colitis, bloody feces, and colon thickness) in a
chemically-induced inﬂammatory bowel disease mouse model (8).
However, no signiﬁcant improvement in disability scores was
observed (not shown). Since the natural product, PB is toxic to
normal cells, derivatives of PB, which is undergoing a clinical trial
for the treatment of cancer with less toxicity (2), may be effectiveagainst autoimmune and inﬂammatory diseases including IBD by
preventing the upregulation of K2P5.1 under disease conditions.
Disclosures
The authors declare no conﬂict of interest.
Author contributions
KT, AS, KE, and SO participated in research design. KT, AS, KE,
and SO conducted experiments. KT, AS, KE, HK, SN, MF, and SO
performed data analyses. KT, AS, and SO contributed to the writing
of the manuscript.
Acknowledgments
This research was supported by JSPS KAKENHI Grant numbers
[JP25460111, JP16K08285] and a research grant from the Supported
Program for the Strategic Research Foundation at Private Univer-
sities, 2013e2017 from the Ministry of Education, Culture, Sports,
Science, and Technology (MEXT). Medical English Service (Kyoto,
Japan) reviewed the manuscript prior to its submission.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2016.10.007.
References
(1) Spitali P, Aartsma-Rus A. Splice modulating therapies for human disease. Cell.
2012;148:1085e1088.
(2) Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel anti-
tumour drugs. Nat Rev Drug Discov. 2012;11:847e859.
(3) Kotake Y, Sanane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al.
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
Nat Chem Biol. 2007;23:570e575.
(4) Pawellek A, McElroy S, Samatov T, Mitchell L, Woodland A, Ryder U, et al.
Identiﬁcation of small molecule inhibitors of pre-mRNA splicing. J Biol Chem.
2014;289:34683e34698.
(5) Ohya S, Kito H, Hatano N, Muraki K. Recent advances in therapeutic strategies
that focus on the regulation of ion channel expression. Pharmacol Ther.
2016;160:11e43.
(6) Enyedi P, Czirja G. Molecular background of leak Kþ currents: two-pore
domain potassium channels. Physiol Rev. 2010;90:559e605.
(7) Bittner S, Bobak N, Feuchtenberger M, Herrmann AM, Gӧbel K, Kinne RW,
et al. Expression of K2P5.1 potassium channels on CD4þ T lymphocytes cor-
relates with disease activity in rheumatoid arthritis patients. Arthritis Res
Ther. 2011;13:R21.
(8) Nakakura S, Matsui M, Sato A, Ishii M, Endo K, Muragishi S, et al. Patho-
physiological signiﬁcance of the two-pore domain Kþ channel K2P5.1 in
splenic CD4þCD25- T cell subset from a chemically-induced murine inﬂam-
matory bowel disease model. Front Physiol. 2015;6:299.
(9) Endo K, Kurokawa N, Kito H, Nakakura S, Fujii M, Ohya S. Molecular identi-
ﬁcation of the dominant-negative, splicing isoform of the two-pore domain
Kþ channel K2P5.1 in lymphoid cells and enhancement of its expression by
splicing inhibition. Biochem Pharmacol. 2015;98:440e452.
(10) Ohya S, Niwa S, Yanagi A, Fukuyo Y, Yamamura H, Imaizumi Y. Involvement of
dominant-negative spliced variants of the intermediate conductance Ca2þ-
activated Kþ channel, KCa3.1, in immune function of lymphoid cells. J Biol
Chem. 2011;286:16940e16952.
(11) Shanmugasundaram R, Selvaraj RK. Regulatory T cell properties of chicken
CD4þCD25þ cells. J Immunol. 2011;186:1997e2002.
(12) Lv K, Zhang Y, Zhang M, Zhong M, Suo Q. Galectin-9 ameliorates Con A-
induced hepatitis by inducing CD4þCD25low/int effector T-cell apoptosis and
increasing regulatory T cell number. PLoS One. 2012;7:e48379.
(13) Kirkegaad SS, Strøm PD, Gammeltoft S, Hansen AJ, Hoffmann EK. The volume
activated potassium channel KCNK5 is up-regulated in activated human T
cells, but volume regulation is impaired. Cell Physiol Biochem. 2016;38:
883e892.
(14) Shin DH, Lin H, Zheng H, Kim KS, Kin JY, Chun YS, et al. HIF-1a-mediated
upregulation of TASK-2 Kþ channels augments Ca2þ signaling in mouse B cells
under hypoxia. J Immunol. 2014;193:4924e4933.
